Sherpa Healthcare Partners

Sherpa Healthcare Partners (夏尔巴投资) is a healthcare-focused investment fund active in China's biotech and life-sciences venture capital landscape. The fund has built a track record of leading or co-leading early-stage rounds across multiple sub-sectors, including single-cell sequencing, AI-enabled drug discovery, and synthetic biology.

Per FreeS Fund and 5Y Capital portfolio updates, Sherpa led the Pre-A round of single-cell sequencing company Singleron Biotechnologies (新格元生物) in 2019 and the A round of AI drug-discovery firm Coherent Biotech (科因生物) in 2021 . It also participated as a follow-on investor in Bota Biosciences' $100 million-plus Series B in 2021, a round that 5Y Capital noted set records for Asian synthetic-biology financing speed and scale . Singleron later raised a nearly $100 million Series B in late 2021, with Sherpa continuing as an existing shareholder alongside Lilly Asia Ventures, ARCH Venture Partners, and others . The fund's positioning appears concentrated on backing platform-level technologies with clinical translation potential, typically entering at Pre-A to A stage and maintaining exposure through later rounds.